Sebia launches M-inSight®, a test for monitoring multiple myeloma patients

Press Release
Dec. 04, 2023

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma

Sebia acquires Zeus Scientific

Press Release
Oct. 12, 2022

The strategic acquisition reinforces Sebia’s product portfolio & strategy in autoimmunity

Sebia Acquires Orgentec Diagnostika

Press Release
Jun. 30, 2021